This mini-review gives a short overview of the novel long-acting GLP-1 RAs albiglutide and dulaglutide and also reviews the studies of liraglutide in treatment of obesity leading to its approval for this use. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.